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Abstract
Background: Identifying stress vulnerability after antidepressant discontinuation may be useful in treating relapses
in depression. Previous studies have suggested significant effects of the immune system as well as the central
nervous system (CNS) on progression and induction of major depression. In the present study, we hypothesized
that the factors that are not rescued by a tricyclic antidepressant imipramine may be associated with stress
vulnerability and relapses in depression.
Methods: To address this issue, mice were exposed to 2 h of restraint stress for 21 consecutive days (chronic
restraint stress (CRS)) with or without co-treatment of imipramine. These groups were exposed to an electronic foot
shock (FS) as additional stress after imipramine washout. Main targets of stress and antidepressants were analyzed
in the hippocampus, lymph node, and serum after a series of depression-like behavior analysis.
Results: In this study, we found for the first time that mice exposed to CRS with a tricyclic antidepressant
imipramine co-treatment, which did not show depressive-like behaviors, were vulnerable to subsequent stressful
stimuli compared to the non-stressed mice after imipramine washout. CRS mice with imipramine co-treatment did
not show any difference in BDNF, serotonin receptors, pro-inflammatory cytokines, or kynurenine pathway in the
hippocampus compared to the controls. However, peripheral IL-4, IL-10, and alternatively activated microglial
phenotypes in the hippocampus were not restored with sustained reduction in CRS mice despite chronic
imipramine administration. Supplementing recombinant IL-4 and IL-10 in co-Imi+CRS mice prevented the stress
vulnerability on additional stress and restored factors related to alternatively activated microglia (M2) in the
hippocampus.
Conclusion: Thus, our results suggest that the reduced IL-4 and IL-10 levels in serum with hippocampal M2
markers may be involved in the stress vulnerability after imipramine discontinuation, and the restoration and
modulation of these factors may be useful to some forms of depression-associated conditions.
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Background
Major depression has various types of symptoms and
disease courses with inconsistent response to treatments
[1]. More than 50 % of patients, who recover from a first
episode of depression, are likely to suffer additional epi-
sode of major depression, resulting in a chronic lifelong
illness [2, 3]. Stress vulnerability constitutes intrinsic
brain abnormality and psychosocial stressful stimuli.
Thus, identifying and characterization of factors related
to stress vulnerability are crucial in management of
major depressive disorders [3].
Involvement of immunology in depression patho-
physiology has been a subject of research interest.
“Cytokine theory of depression” proposed that cyto-
kines are associated with the pathogenesis of depres-
sion by communicating with the central nervous
system (CNS) [4, 5]. Numerous studies have reported
that circulating pro-inflammatory cytokines, such as
interleukin-1 beta (IL-1β), IL-6, interferon gamma (IFN-γ),
and tumor necrosis factor alpha (TNF-α), may be
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associated with some forms of major depression [6]. Indo-
leamine 2,3-dioxygenase (IDO) has been suggested as a fac-
tor linking “cytokine theory” and “monoamine theory” in
depression, since it is activated by pro-inflammatory cyto-
kines and metabolizes tryptophan with downstream en-
zymes, leading to serotonin reduction and neurotoxicity
[7, 8]. A tricyclic antidepressant imipramine functions by
inhibiting serotonin and norepinephrine reuptake, and it
was found to have anti-inflammatory effects [9]. However,
inconsistent findings regarding effects of stress on inflam-
matory cytokines are reported, and inflammation-focused
involvement of immunology in depression remains con-
troversial [10].
Anti-inflammatory cytokines also have been known to
be involved in the pathophysiology of depression and
stress response [4, 11]. Previous studies have suggested
that anti-inflammatory cytokines affect depressive behav-
ior as a failure to counterbalance the increased expres-
sion of pro-inflammatory cytokines [12, 13]. The ratio of
IFN-γ to IL-10 was elevated in depressed patients, and it
was normalized after prolonged antidepressant treat-
ment [14, 15]. T cells, such as regulatory T cells (Treg),
may communicate with the CNS via anti-inflammatory
functions during stressful episodes, and impaired T cell
function may directly contribute to the depression
pathogenesis [16]. These findings support and suggest
that anti-inflammatory cytokines with T cells may par-
ticipate in the common pathway in depression and other
psychophysiological activities [13].
As part of the innate immune system within the CNS,
microglia was found to be involved in the pathophysiology
of depression [17, 18]. Although classification is oversim-
plified, microglia can exhibit classically activated M1
phenotype or M2 phenotype with alternate activation [19].
In vitro, M1 microglia are induced by lipopolysaccharide
(LPS) and express pro-inflammatory cytokines, such as
IL-1β, TNF-α, and IL-6 [19, 20]. M2 microglia express
CX3CR1, CD200R, and CD206 to show neuroprotective
effect and homeostatic maintenance [19, 20]. Previous
studies found changes in microglial proliferation and acti-
vation in mice that were exposed to chronic restraint
stress or social defeat stress [21–23]. However, the rela-
tionship between peripheral cytokines and microglial phe-
notypes has not been elucidated in depression until now.
We found for the first time that stress vulnerability
could be induced in the mice that were exposed to chronic
restraint stress (CRS) with imipramine co-treatment by
acute stressor after imipramine discontinuation. Chronic
imipramine co-treatment inhibited stress-related behav-
iors but failed to normalize the decreased peripheral IL-4
and IL-10 and hippocampal M2 microglia factors. In
addition, supplement of IL-4 and IL-10 prevented the
stress vulnerability with normalization of M2 microglia
factors in the hippocampus. Thus, our results propose
potential of IL-4 and IL-10 to dampen elevated vulnerabil-




Male C57BL/6 mice at age of 7 weeks (Orient Bio Inc.
Seoul, Korea) weighing 20–25 g were used for all the exper-
iments. Animals were housed five per cage in a room main-
tained at 22 ± 0.5 °C with an alternating 12-h light–dark
cycle. Food and water were available ad libitum. Animals
were allowed to acclimate to the laboratory 1 week before
the beginning of the experiments. To reduce variation, all
experiments were performed during the light phase of the
cycle. All experimental procedures were approved by the
Animal Care and Use Committee of the CHA University
(IACUC130018).
Drug treatment and stressful stimuli exposure timeline
Experiment 1: restraint stress and imipramine treatment
Animals were randomly assigned to a non-stressed
control group or a CRS group, and CRS mice were ran-
domly divided and received either normal saline or im-
ipramine (20 mg/kg) co-treatment (co-Imi+CRS).
Imipramine (Sigma-Aldrich, St. Louis, Missouri) was
dissolved in physiologic normal saline and was admin-
istered intraperitoneally 30 min prior to restraint
stress. For restraint stress, the mice were forced into
50 mL Corning tubes with a nose-hole for ventilation,
2 h per day (11:00 AM–1:00 PM). The mice were ex-
posed to restraint stress (2 h/day) for 21 consecutive
days (CRS). A series of behavior assays were performed
within a week after the discontinuation of CRS and im-
ipramine co-treatment. The hippocampus and the
mesenteric lymph nodes were dissected 1 day after be-
havior assessments for Western blot and qPCR ana-
lysis. The whole blood was collected by cardiac
puncture.
Experiment 2: post-short-term restraint stress and electrical
foot shock
After 21 days of restraint stress and imipramine admin-
istration, mice had resting period of 5 days to allow the
drug to be completely washed out [24]. During the
washout period, depressive-like behaviors of mice were
assessed using sucrose preference (SP) test, elevated plus
maze (EPM), and tail suspension test (TST). After 5 days
of resting period, foot shock (FS) was delivered in an
electrical FS chamber with a grid floor that is connected
to an electric shock generator. Mice received a 0.25-mA
electrical current of 1-s duration delivered randomly for
10 times over 10 min [25]. Depressive-like behaviors
were assessed again 3 days after electrical FS using SP
test, light–dark (LD) box, and forced swim test (FST).
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Experiment 3: IL-4 and IL-10 combination treatment
Experiment 2 described above is repeated with cytokine
treatment during the 5-day washout period. Co-Imi
+CRS group was randomly assigned to saline or a com-
bination of recombinant mouse IL-4 and IL-10 (R&D
Systems, Minneapolis, USA). For 5 days, mice were
treated by ip injection of saline or combination of cyto-
kines (100 ng of IL-10 and 100 ng of IL-4). Mice were
then exposed to electrical FS stress (identical procedure
as described above), and their depression-like behavior
was assessed 3 days after the additional stress exposure.
The hippocampus and the mesenteric lymph nodes were
dissected 1 day after behavior assessments for further
molecular analysis.
Behavioral testing
Mice were allowed to acclimate to a testing room for
at least 30 min before performing the assessments.
All assessments were conducted during the light cycle
between 9:00 AM and 4:00 PM in a series, one as-
sessment per day. SP test was performed independ-
ently. LD test and EPM were done using EthoVision
XT9 video tracking system (EthoVision®, Version 9
Noldus, Netherlands). TST and FST were conducted
by two observers to minimize error.
Sucrose preference test
Preference for sucrose solution over drinking water was
measured in order to assess anhedonia, which is usually
altered in depressed mice [26]. To assess SP, mice were
provided with two bottles filled with 1 % sucrose diluted
in drinking water or drinking water alone. Animals were
acclimatized to two bottle conditions for two consecutive
days and were tested for their choice for two additional
days. The position of the bottles was interchanged during
4 days of testing. On each test day, the fluid levels were
noted. SP was calculated as percentage of sucrose/total
fluid consumed.
Light–dark exploration
Anxiety-like behavior was measured using EPM and
LD by assessing their tendency to avoid bright light
and open spaces [27, 28]. The apparatus used in this
assessment was a box (30 × 30 × 30 cm) consisting of
one brightly lit open chamber connected to a dark-
ened enclosed chamber. The chambers were con-
nected by a small square hole (7 × 7 cm). Mice were
placed in the corner of the lit chamber, facing away
from the dark chamber, and the number of transitions
between the chambers and time spent in the dark
chamber were manually measured for 10 min. The
times spent in each room were recorded using EthoVision
XT9 video tracking system (EthoVision®, Version 9
Noldus, Netherlands).
Elevated plus maze
EPM apparatus and procedure are modified from the
original protocol [28]. The apparatus consisted of four
open roof arms (30 × 5 cm) made of white matte Plexi-
glass. The two opposite arms were enclosed with 20-cm-
high walls, and the remaining two opposite arms had no
walls. The four arms were placed at 90° to each other
around a 5 × 5-cm square in the center. The apparatus
was elevated 30 cm above the floor. The mouse was ini-
tially placed in the center of the apparatus, facing one of
the open arms away from an experimenter, and was
allowed to explore the apparatus freely for 5 min. The
number of entries to open arms and closed arms was re-
corded, and the times spent in each arms were recorded
using EthoVision XT9 video tracking system (EthoVision®,
Version 9 Noldus, Netherlands).
Tail suspension test
The immobility induced by tail suspension was modified
from a method described by Steru et al. [29]. The appar-
atus consisted of a cupboard with a hook attached to the
top. The mice were suspended by securing the tail to the
hook by wrapping adhesive tape around the tail. The tail
was suspended carefully not to fold the tail, and the tip
of the tail was wrapped 2 cm away from the top of the
hook. The data of the mice that climbed their tails were
removed from the test. The time spent immobile during
a 7-min testing period was measured. The observers
were blinded to the groups. The time spent immobile
was measured and compared by two observers to
minimize the bias.
Forced swimming test
In FST, we assessed the ability of mice to cope with an
inescapable stressful situation, which reflects depressive-
like behavior [30]. Mice were individually placed in a 2-L
Pyrex beaker (13 cm diameter, 24 cm height), filled with
23 °C water with a depth of 17 cm. All mice were forced
to swim for 6 min, and the duration of immobility was
measured during the final 5 min of the test. The immo-
bility was defined as the time that the mouse spent float-
ing without struggling and making only the movements
necessary to keep its head above the water level. The ob-
servers were blinded to the groups. The time spent im-
mobile was measured and compared by two observers to
minimize the bias.
Determination of glucocorticoid level
CRS mice were immediately sacrificed after the last re-
straint stress, and whole blood was collected by cardiac
puncture, and serum was isolated and stored at −80 °C
until assayed. Serum glucocorticoid level was determined
by corticosterone EIA kit according to manufacturer’s
instructions (Cayman Chemical, Ann Arbor, MI).
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Total protein extraction and Western blot analysis
Hippocampal protein was extracted and expression levels
were assessed using Western blotting. After dissecting the
hippocampus, the tissue was washed two times with cold
Tris-buffered saline (TBS; 20-mM Trizma base and
137 mM NaCl, pH 7.5). Immediately after washing, cells
were lysed with SDS lysis buffer (62.5-mM Trizma base,
2 % w/v SDS, 10 % glycerol) containing 0.1 mM Na3VO4,
3 mg/ml aprotinin, and 20 mM NaF. After brief sonication
to shear DNA and reduce viscosity, the concentration of
protein was determined with a detergent-compatible pro-
tein assay reagent (Bio-Rad Laboratories) using bovine
serum albumin as the standard. After adding dithiothreitol
(5 mM) and bromophenol blue (0.1 % w/v), the proteins
were boiled, separated by electrophoresis in 10–16 %
polyacrylamide gels (Invitrogen), and transferred onto a
polyvinylidene difluoride (PVDF) membrane (Bio-Rad
Laboratories). Membranes were blocked on a shaker for
1 h at room temperature. Blocking buffer consisted of
TBST (Tris-buffered saline/0.1 % Tween-20) and 5 % skim
milk. Primary antibodies were dissolved in the blocking
buffer and the membranes were immunoblotted with anti-
bodies against brain-derived neurotrophic factor (BDNF;
1:1000, Abcam), serotonin receptor 1A (5-HT1A; 1:1000,
Santa Cruz) and serotonin receptor 2A (5-HT2A; 1:1000,
Santa Cruz), IDO (1:500, Abcam), CX3CR1 (1:400, Abcam),
and beta-actin (1:1000, Cell Signaling). The membranes
were incubated in the anti-rabbit (1:2000, Cell Signaling) or
anti-goat IgG secondary antibodies (1:2000, Santa Cruz)
dissolved in the blocking buffer at a room temperature for
an hour. The membranes were visualized with ECL-plus
solution (Amersham Pharmacia Biotech). Then, the mem-
branes were then exposed to chemiluminescence (LAS-
4000, Fujifilm) for detection of light emission. Western blot
results were scanned on a densitometer and quantified
using MultiGauge (Fujifilm).
Quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR)
The whole hippocampus and the mesenteric lymph
nodes were dissected a day after behavior assessments
for experiments 1 and 3. For RNA extraction, the frozen
hippocampus or mesenteric lymph node was homoge-
nized in 1 mL of QIAzol reagent per 100 mg of tissue
(Qiagen, Valencia, CA). Chloroform was added to separ-
ate the phase that contains RNA, and isopropyl alcohol
was added to precipitate RNA. The precipitated RNA
pellet was re-dissolved in DEPC-treated water (Bioneer,
Seongnam, Korea) after air-drying the pellet. Quantifica-
tion of RNA concentration was determined by the ab-
sorption at 260 nm. One microgram of messenger RNA
(mRNA) was reverse-transcribed into cDNA in 20 μL of
reaction mix using Maxime RT PreMix Kit (Intron,
Seongnam, Korea). Quantitative PCR was performed
using AccuPower GreenStar qPCR PreMix (Bioneer,
Seongnam, Korea). Primer sequences are listed in
Table 1. The cyclic conditions consisted of an initial en-
zyme activation at 95 °C for 5 min followed by 40 cycles
of denaturation at 95 °C for 20 s, annealing, and exten-
sion including detection of SYBR Green bound to PCR
product at 56 °C for 40 s. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as an internal con-
trol for normalization. The relative quantities of PCR
fragments were calculated using the comparative CT
method.
Serum cytokine assay
Serum cytokine levels were measured using Bio-Rad
Bio-Plex® assay (Bio-Rad, Hercules, CA). The lower de-
tection limits of IL-1β, IL-4, IL-6, IL-10, IL-17, TNF-α,
and IFN-γ were 9.4, 2.1, 0.2, 1.0, 0.8, 1.2, and 1.4 pg/mL,
respectively. The cytokine levels were measured and an-
alyzed according to the manufacturer’s instruction.
Statistical analysis
Data were presented as the mean ± standard mean error
(SEM). The statistical significance of differences be-
tween groups was assessed with Student’s t test and
one-way or two-way analysis of variance (ANOVA)
using GraphPad Prism version 5.0 for Mac (GraphPad,
La Jolla, CA). Bonferroni’s post hoc analysis was per-
formed when p values were <0.05.
p < 0.05 was considered as statistically significant.
Results
CRS-induced depression-like behaviors and chronic
imipramine treatment reversed the depressive-like
behaviors
Animals were exposed to CRS in reference to the previous
study that reported changes in behaviors and molecular
mechanisms that are relevant to depression [31, 32]. In
LD, CRS mice spent more time in the dark compared to
the controls, and imipramine treatment reduced the time
spent in the dark (Fig. 1a, b). Similarly, CRS mice exhib-
ited lower percentages of the time spent in the open arms
than the controls and spent more time in the closed arms
in EPM (Fig. 1a, c). Moreover, CRS mice exhibited a sig-
nificant decrease in SP compared to the controls (Fig. 1d).
Imipramine co-treatment to CRS mice (co-Imi+CRS) pre-
vented the decrease in SP and normalized the preference
similar to that of the controls. In both TST and FST, ex-
posure to CRS increased immobility compared to the con-
trols, suggesting that CRS mice exhibited depression-like
behaviors. Imipramine treatment significantly decreased
the immobility time, and this shows that imipramine was
successful to prevent behavioral despair induced by CRS
in both TST and FST (Fig. 1e, 1f). Imipramine treatment
to the controls did not affect stress-related behavior
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(Additional file 1: Figure S1). The glucocorticoid (Gc)
level was elevated immediately after termination of CRS
(F1, 20 = 33.60, p = 0.0004), which suggests that habitu-
ation did not occur in response to the chronic restraint
procedure used in the current study. Chronic imipra-
mine treatment did not alter Gc levels in the controls
and in CRS mice, and this indicates that imipramine
does not affect HPA axis activation (Fig. 1g). Collect-
ively, 3 weeks of restraint stress induced significant
changes in behaviors that are associated with the charac-
teristics of chronic psychological stress, and imipramine
co-treatment prevented induction of stress-associated
behaviors.
CRS mice with imipramine co-treatment exhibited
depressive-like behaviors when exposed to a short-term
acute stress after imipramine washout
Co-Imi+CRS was further assessed for its vulnerability
for depressive-like symptoms when exposed to an add-
itional stressor after termination of CRS and imipramine.
The experimental schedule is described in Fig. 2a. FS
stress was assessed as an additional stressor. The con-
trols and the CRS mice were divided into two groups,
and one group received FS and the other group was put
in the shock chamber for 10 min without electrical stim-
uli. As shown in Fig. 2b, CRS was found to have a sig-
nificant effect and increased stress-associated behaviors
in all behavior assays (SP, F1, 20 = 12.21, p = 0.0023; LD,
F1, 32 = 24.41, p < 0.0001; FST, F1, 41 = 36.60, p < 0.0001).
However, FS itself in controls and CRS mice did not
have any significant effect on stress-associated behaviors
in all of the behavior assays (SP, F1, 20 = 0.005616, p =
0.9410; LD, F1, 32 = 0.09017, p = 0.7659; FST, F1, 41 = 3.697,
p < 0.0615).
After confirming that FS did affect behavior assay in
controls and CRS mice, preliminary behavioral tests
were done during the imipramine washout period and
confirmed the effects of CRS and imipramine (Fig. 2c).
Imipramine washout itself did not induce depression-
like behaviors in co-Imi+CRS (data not shown). The
controls, CRS, and co-Imi+CRS mice were exposed to FS
(CON+FS, CRS+FS, and (co-Imi+CRS)+FS, respectively),
and depression-associated behaviors were assessed. After
FS exposure, both CRS+FS and (co-Imi+CRS)+FS showed
depression-like behaviors in SP, LD, and FST while CON
+FS did not (Fig. 2d). When 3 days of RS was introduced
as an additional stressful stimulus, it also induced
depression-like behaviors in all groups, except for the
Table 1 List of primers that were used in qRT-PCR
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controls without previous stress exposure (data not
shown). These results indicate that co-Imi+CRS mice ex-
hibit both anxiety-like just like CRS and depression-like
symptoms when exposed to FS with imipramine washout,
even though they did not exhibit depressive-like behaviors
before. In sum, co-Imi+CRS mice seemed to be more vul-
nerable to additional stressful stimuli compared to the
controls after imipramine washout, and this implies that
chronic imipramine treatment was not successful to
normalize the detrimental effects of CRS comprehensively.
Imipramine co-treatment could not normalize M2
microglia factors in the hippocampus of the CRS
Based on the hypothesis that the factors that are not res-
cued by antidepressant may be associated with stress
vulnerability, we examined the main targets of stress and
antidepressant in the hippocampus using qPCR and
Western blot. As shown in Fig. 3a, b, BDNF was reduced
significantly in CRS mice and was reversed by imipra-
mine co-treatment, and this change was confirmed by
Western blotting. Although we examined that mRNA
levels of TNF-α, IL-6, KMO, and KAT were increased
within a short time (6 h) after the final restraint stress
session, the mRNA levels of IDO, kynurenine pathway
enzymes (KAT and KMO), TNF-α, IL-1β, and IL-6 were
not altered by CRS mice or imipramine co-treatment
which was analyzed after behavior assessments (at least
7 days after final restraint stress session) (Fig. 3a). 5-HT1A,
5-HT2A and IDO expression did not show a difference
across the groups (Fig. 3a, b).
Since it has been reported that chronic stressful
stimuli may contribute to changes in hippocampal
Fig. 1 Chronic restraint stress-induced anxiety-like and depressive-like behaviors and imipramine co-treatment prevented the induction of
stress-related behaviors. Mice were exposed to restraint stress for 21 days (CRS) with saline or imipramine (20 mg/kg; co-Imi+CRS). A serial
of behavioral assessments were finished within a week after the termination of CRS and imipramine co-treatment. Anxiety-like behaviors,
such as light–dark (LD) box and elevated plus maze (EPM), were assessed using EthoVision XT9 (a). LD the time spent in the dark zone
during the 10 min was measured (b). EPM the time spent in the open arms was measured and was expressed as a percentage (c). Sucrose
preference (SP) for 1 % sucrose solution over regular drinking water was examined for 2 days after 2 days of inhabitation to two bottle
conditions (d). Tail suspension test (TST) was done for a 7-min period, and the duration that the subject remained immobile was calculated
(e). Forced swimming test (FST) was done for 5 min following a minute of pre-swimming, and the total immobility time after the pre-swimming
was measured (f). *p < 0.05, **p < 0.01, ***p < 0.001 compared with the controls unless indicated otherwise with an arrow, n = 10–13 in each group
and the data shown are mean ± standard mean error (SEM). Serum glucocorticoid level (Gc level) was analyzed immediately after CRS by performing
enzyme-linked immunosorbent (EIA) assay (g). **p < 0.01 compared with the controls, n = 5 in each group and the data shown are mean ± standard
mean error (SEM)
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Fig. 2 (See legend on next page.)
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microglial effector phenotypes [10, 33], we examined
the changes in hippocampal microglial phenotype
markers. Immunoreactivity of ionized calcium-binding
adaptor molecule-1 (Iba-1), a microglial marker, did
not show a significant difference in co-Imi+CRS mice
compared to the controls (data not shown). There was
no difference in NADPH oxidase (NOX2), an M1
microglia marker, across the groups (Fig. 3c). However,
M2-related markers, CX3CR1 and CD200R, were de-
creased in the hippocampus of the CRS mice, and
chronic imipramine treatment was not successful to
reverse this decrease (Fig. 3c). CD206, another M2
microglia marker, also showed the same trend as
CX3CR1 and CD200R but lacked statistical signifi-
cance (Fig. 3c). Our results suggest that imipramine
can normalize the hippocampal factors that were trad-
itionally considered to contribute to depression in all
groups. However, the reduced M2-related markers in
CRS mice were not normalized by the imipramine
treatment. These results suggest that vulnerability to
additional stressful stimuli may be due to M2-related
factors, not the usual depression-related factors.
Imipramine co-treatment did not prevent sustained
reduction of IL-4 and IL-10 levels in the lymph nodes and
the serum of CRS
The immune system is reported to be involved in the de-
pression pathophysiology and stress responses [4, 34].
As shown in Fig. 4a, mRNA levels of forkhead box P3
(FOXP3; a Treg-specific transcription factor) and GATA3
(a Th2-specific transcription factor) were decreased in
CRS mice, and imipramine co-treatment did not reverse
the reduced FOXP3 and GATA3 mRNA. GATA3 ap-
pears to be decreased in Co-imi+CRS compared to the
CRS mice but lacked statistical significance. T box 21
(TBX21; a Th1-specific transcription factor) and RAR-
related orphan receptor gamma (RORγ) expression, a
transcription factor of Th17, remained constant in both
the controls and CRS mice. The mRNA levels of IL-4,
IL-10, and IL-13 were significantly decreased in CRS
and not rescued by imipramine co-treatment. IL-1β and
IL-6 levels also were decreased but rescued by
imipramine co-treatment. IFN-γ, TNF-α, and IL-17 did
not exhibit any difference across all groups (Fig. 4a).
To confirm whether the alteration of cytokine mRNA
in the lymph nodes is related with the serum level, the
circulating cytokines IL-4, IL-10, IFN-γ, TNF-α, IL-1β,
IL-6, and IL-17 were measured by Bio-Plex® cytokine
assay, and we confirmed the immunomodulatory effect
of imipramine in CRS mice. The ratio of IFN-γ to IL-10
was calculated using the level measured in this assay and
showed a significant increase in CRS, and imipramine
treatment reversed this increase (Fig. 4b). Serum IL-4
and IL-10 levels were reduced in CRS mice, and IL-4
level was not reversed by imipramine (Fig. 4b). IL-10
level was reversed partially by chronic imipramine co-
treatment, and it was still reduced in co-Imi+CRS mice
compared to the controls (Fig. 4b). TNF-α, IL-1β, and
IL-6 were significantly decreased by CRS but were re-
stored by imipramine co-treatment (Fig. 4b). There was
no significant change in IL-17 upon exposure to CRS or
co-Imi+CRS. The change in serum cytokines was similar
to the change observed in the lymph nodes. These data
indicate a possible association of stress vulnerability with
sustained reduction in anti-inflammatory cytokines with
reduced levels of Treg and Th2 transcription factors des-
pite the prolonged antidepressant treatment.
IL-4 and IL-10 supplements prevented vulnerability to
subsequent stressful stimuli in CRS mice with imipramine
co-treatment, preventing the induction of depression-like
behaviors
Since the levels of IL-4 and IL-10 remained decreased des-
pite the chronic imipramine treatment, we supplemented
100 ng of each mouse recombinant IL-4 and IL-10 to
co-Imi+CRS mice to assess whether immune balance by
these supplements can prevent the induction of
depression-like behaviors upon an exposure to an add-
itional stressful stimulus. First, antidepressant effect of
combination of IL-4 and IL-10 (IL-4/10) themselves was
assessed at the dose. The controls and the CRS mice were
divided into two groups, and one group was injected with
saline and the other group was injected with 100 ng of
each IL-4 and IL-10 for 5 days. As shown in Fig. 5a, CRS
mice showed depressive-like behaviors (SP, F1, 23 = 16.40,
(See figure on previous page.)
Fig. 2 CRS mice with imipramine co-treatment exhibited anxiety-like and depressive-like behaviors upon an exposure to short-term acute stress.
Drug treatment and stressful stimuli exposure timeline: CRS, chronic restraint stress; SP, sucrose preference test; EPM, elevated plus maze; TST, tail
suspension test; RS, restraint stress; LD, light–dark box; FST, forced swimming test (a). Depressogenic effect of foot shock stress was assessed, and
foot shock stress alone does not affect anxiety-like or depressive-like behaviors in the non-stressed (CON) and CRS mice (b). Prior to the exposure
to foot shock, CRS mice with imipramine co-treatment (co-Imi+CRS) did not exhibit anhedonic behavior (sucrose preference test, SP), anxiety-like
behaviors in EPM, and depressive-like behaviors in TST compared with CON (c). However, following the exposure to electric foot shock, they
(co-Imi+CRS) showed decreased sucrose preference, exhibited anxiety-like behavior in LD, and depressive-like behaviors in FST compared with
CON (d). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with the controls unless indicated otherwise with an arrow, n = 8–10 in each
group and the data shown are mean ± standard mean error (SEM). Three times independent experiments was performed, giving a total of nine
per group in the final analysis for Western blot
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p = 0.0005; LD, F1, 32 = 13.88, p = 0.0008; FST, F1, 30 =
14.49, p = 0.0006). However, IL-4/10 treatment itself did
not have any significant effect on non-stressed (con-
trols) or CRS mice in the behavior assays (SP, F1, 23 =
1.636, p = 0.2136; LD, F1, 32 = 0.2902, p = 0.5938; FST, F1,
30 = 1.499, p = 0.2304). IL-4/10 treatment did not affect
BDNF and CX3CR1 expression in Western blot and has
no change in mRNA levels of CX3CR1, CD200R, and
CD206 (Fig. 5b, c). These data indicate that the combin-
ation of IL-4 and IL-10 itself did not have an antidepres-
sant effect at this dose.
After confirming the absence of antidepressant effect
of IL-4/10, we investigated whether IL-4/10 prevents
stress vulnerability in co-Imi+CRS mice. During the
5 days of resting period after the termination of CRS,
co-Imi+CRS mice were randomly divided into two
groups, and each group received saline or IL-4/10. After
the cytokine treatment, the mice were exposed to an epi-
sode of electric FS, and depressive-like and anxiety-like
behaviors were assessed. In all behavioral assays (SP,
EPM, TST, and FST), (co-Imi+CRS)+FS mice with saline
injection exhibited similar depression-like behaviors to
CRS+FS mice (Fig. 5c). However, we found that IL-4/10
alleviated depression-like behaviors that were observed
in (co-Imi+CRS)+FS mice (Fig. 5c). Even though the
combination of IL-4/10 itself did not have an antidepres-
sant effect, it prevented depression-like behaviors in the
co-Imi+CRS mice that were exposed to additional stres-
sor after imipramine washout. These results suggest that
promoting peripheral immune balance by supplementing
IL-4/10 could be the missing key that imipramine failed
to reverse in CRS mice, and they may contribute to
lower the vulnerability to additional stressful stimuli.
M2 microglia phenotype may be associated with IL-4 and
IL-10 combination treatment that lowered stress
vulnerability
To confirm the correlation between M2 microglia
phenotype and IL-4/10 combination treatment, the M2
microglia markers were assessed in the hippocampus of
(co-Imi+CRS)+FS mice and their counterparts. As
shown in Fig. 5d, the combination of IL-4/10 reversed
the reduced mRNA expressions of CX3CR1, CD200R,
and CD206 that was not rescued imipramine co-
treatment in co-imi+CRS mice with FS exposure. In
sum, supplement of IL-4/10 was successful to reverse
the change in level of M2 microglia markers, which may
be associated with an additional mechanism of IL-4/10
in lowering the vulnerability towards additional stressful
stimuli.
Discussion
Identifying stress vulnerability after antidepressant discon-
tinuation may be useful in treating relapses in depression.
In this study, we attempted to find the answer for decreas-
ing vulnerability to additional stressful events in subjects
who had previous depressive episode with imipramine dis-
continuation. We found for the first time that imipramine
could not prevent vulnerability to additional stressful
stimuli after imipramine discontinuation although imipra-
mine co-treatment to CRS mice inhibited induction of
depressive-like behaviors due to its anti-stress effect. The
stress vulnerability appears to be related to the decreased
serum IL-4 and IL-10 levels despite the imipramine treat-
ment. Thus, we propose that IL-4 and IL-10 may be able
to lower the vulnerability to some forms of stress- and
depression-related conditions after imipramine discon-
tinuation. In addition, M2 microglia phenotype restoration
by IL-4/10 in the hippocampus may be a possible mechan-
ism in lowering the vulnerability towards additional stress-
ful stimuli.
Assuming that the factors that were not recued by im-
ipramine may be involved in the stress vulnerability of
co-Imi+CRS mice, we examined the effect of imipramine
on alteration of BDNF, serotonin receptors, pro-
inflammatory cytokines, components of kynurenine
pathway, and microglial phenotype markers in the
hippocampus of the mice. BDNF, serotonin receptors,
and IDO have been known as main targets of stress and
antidepressants in the hippocampus [35, 36]. Microglia
are responsible for homeostasis maintenance, neuron
support, and neurogenesis, and reports have shown that
microglia and neuroinflammation may be involved in de-
pression pathophysiology [10, 19, 37]. In accordance to
(See figure on previous page.)
Fig. 3 Depression-related factors in the hippocampus were normalized by imipramine co-treatment while M2-related microglia phenotypes were
not rescued by imipramine. CRS was conducted for 2 h/day for 21 consecutive days by placing the mouse in a 50-mL Corning tube, and 20 mg/
kg of imipramine was administered intraperitoneally 30 min prior stress. The mice were sacrificed 1 day after Fig. 1 of behavior assessment. The
hippocampi were dissected for quantitative reverse transcriptase polymerase chain reactions (a, c) and Western blot (b) analysis. Quantitative
reverse transcriptase polymerase chain reactions were done using mRNA extracted from the mouse hippocampus (n = 10–15). The CT values were
normalized as a ratio as controls being 1, which is indicated by dotted lines (a). Western blot analysis was done using 50 μg of total protein
extracted from the mouse hippocampus (n = 3). Expressed BDNF, serotonin receptor 1A (5-HT1A), serotonin receptor 2A (5-HT2A), IDO, CX3CR1, and
β-actin were quantified using MultiGauge application (Fujifilm) (b). Changes in mRNA of NADPH oxidase (NOX2) and M2 microglia markers, such
as fractalkine receptor (CX3CR1), CD200 receptor (CD200R), and CD206, were measured (n = 7–10). RQ value refers to the ratio of respective factors
as a percentage of the controls (c). The data shown are mean ± standard mean error (SEM) *p < 0.05, ***p < 0.001 compared with the controls
unless indicated otherwise with an arrow
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previous studies [38], BDNF, IDO, and pro-inflammatory
cytokine levels did not show significant difference be-
tween controls and co-Imi+CRS mice. However, we
found that alternative M2 microglia markers, such as
CD200R, CX3CR1, and CD206, were reduced in the
hippocampus of CRS mice and were not normalized by
imipramine treatment. Despite chronic imipramine co-
treatment, it could not prevent vulnerability to add-
itional stressful stimuli, and it is speculated to be due to
a failure to rescue the M2 microglia phenotype in the
hippocampus. This suggests that vulnerability to a sub-
sequent stress may be associated with the changes in
M2 phenotypes of microglia, not the main targets of
stress and antidepressant in the hippocampus, even
though we cannot exclude other brain regions that are
also implicated in depression pathophysiology.
Here, imipramine was chosen as an antidepressant,
since it has been extensively demonstrated to inhibit the
production of pro-inflammatory cytokines and to pro-
duce anti-inflammatory cytokines [14, 15, 39]. However,
most of these studies were based on ex vivo or in vitro
immunological experiments using co-incubation of the
whole blood of depressed patients with imipramine so
they bear some limitation [9, 14, 15, 40]. In the present
study, imipramine co-treatment was successful to
normalize the IFN-γ and IL-10 production ratio but
could not normalize the absolute levels of IL-4 and IL-
10. In addition, transcription factors of Th2 and Treg,
which are one of the main producers of IL-4 and IL-10
in T cells [41], were not restored by imipramine. Fur-
thermore, stress vulnerability to FS was examined in
nude mice, which lacked T cell-mediated immunity, but
not in their counterpart mice, Balb/c (Additional file 1:
Figure S2). These results suggest that stress vulnerability
may be related to impaired T cell function, specifically
IL-4 and IL-10 production. Although imipramine co-
treatment restored peripheral pro-inflammatory cyto-
kines, such as TNF-α, IL-1β, and IL-6, it was not suc-
cessful to restore the number of leukocytes reduced by
CRS in the blood, spleen, and lymph node (Additional
file 1: Figure S3). This result suggests that imipramine
may exert immunomodulatory effect by targeting certain
subsets of leukocytes. Previous studies have reported that
progression and consequence of depression may depend
on integrity of the peripheral immune system and chronic
stress can impair T cell immunity [42–44]. Additionally,
IL-4 and IL-10 are suggested to play a significant role in
affecting depression-like behaviors [13, 43, 45, 46]. In the
present study, the combination of IL-4 and IL-10 pre-
vented the stress vulnerability in co-Imi+CRS mice that
encountered additional stressful stimuli after imipramine
discontinuation, even though it did not have an anti-
depressant effect in the controls or CRS mice. Therefore,
we speculated that downregulation of IL-4 and IL-10 may
be the impairment in a stress-coping mechanism, which
may contribute in developing vulnerability to additional
stress-related events.
There are several possible ways that led to changes in
microglia by IL-4/10 injection. Chronic physical stress
accounts as distress and several reports have reported
impaired blood–brain barrier (BBB) permeability in
major depressive disorders [47, 48]. Previous study has
suggested peripheral immune imbalance is often accom-
panied by impairment of the BBB, which may allow the
entry of IL-4 and IL-10 into the parenchyma [49]. Previ-
ous study has found that bone marrow-derived mono-
cytes infiltrated into the paraventricular nucleus upon
exposure to chronic psychological stress, which may be
associated to regional neuronal and microglial activation
[50, 51]. Whether peripheral cytokines reach to paren-
chyma through the BBB, peripheral cytokine signaling
can induce behavioral modification through receptors on
the endothelial cells [47, 51, 52]. IL-4 and IL-10 inside
the CNS were found to exert its beneficial effect on cog-
nition and memory by alternatively activating microglia
(M2) upon interaction with the respective receptors on
the microglial cells [19, 53–55]. Previous study has
established that CNS microenvironment affects micro-
glial cell function and suggested that microglia’s auto-
regulating ability was one of mechanisms for the CNS
immunosuppressive state maintenance [53]. The choroid
plexus and the cerebrospinal fluid (CSF) environment
was found to be an important immunomodulatory gate
that can skew immune cells towards alternately activated
state due to high levels of the Th2 cells and M2 macro-
phage skewing cytokines in the CSF [56]. Activated per-
ipheral T cells can shape the CNS by entering the
endothelium of the choroid plexus into the cerebrospinal
fluid and communicate with the microglia and by modu-
lating and altering the microglial phenotypes [37, 57, 58].
(See figure on previous page.)
Fig. 4 The reduced IL-4 and IL-10 with Th2- and Treg-related transcription factors were not rescued by imipramine treatment. CRS was conducted for
2 h/day for 21 consecutive days by placing the mouse in a 50-mL Corning tube, and 20 mg/kg of imipramine was administered intraperitoneally
30 min prior stress. The mice were sacrificed 1 day after Fig. 1 of behavior assessment. The mesenteric lymph nodes (a) were dissected for quantitative
reverse transcriptase polymerase chain reactions and serum (b) was obtained to measure circulating levels of pro-and anti-inflammatory cytokines
using Bio-Rad Bio-Plex® assay. The CT values were normalized as a ratio as controls being 1, which is indicated by dotted lines. RQ value refers to the
ratio of respective transcription factors as a percentage of the controls. *p < 0.05, **p < 0.01, ***p < 0.001 compared with the controls, n = 10–15 per
group and the data shown are mean ± standard mean error (SEM)
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Fig. 5 Supplement of IL-4 and IL-10 prevents stress vulnerability following imipramine discontinuation with restoration of type 2 microglia marker
messenger RNAs. A combination of IL-4 (100 ng) and IL-10 (100 ng) for 5 days was treated intraperitoneally in non-stressed mice (controls) and
CRS mice. A combination of IL-4 (100 ng) and IL-10 (100 ng) for 5 days itself does not have an antidepressant-like effect in controls or CRS mice
(a). The combination of IL-4 and IL-10 for 5 days does not alter the depression-associated factors, BDNF, and M2-related microglia factor, CX3CR1,
in the hippocampus (b). Effect of IL-4 and IL-10 in preventing stress vulnerability and depressive-like behaviors of co-Imi+CRS mice was assessed
using sucrose preference (SP) test, elevated plus maze (EPM), tail suspension test (TST), and forced swimming test (FST) (c). Changes in M2 microglia marker
expressions, such as fractalkine receptor (CX3CR1), CD200 receptor (CD200R), and CD206, were measured 1 day after (c) of behavior assays (d). RQ value
refers to the ratio of respective factors as a percentage of the controls. +p< 0.05, +++p< 0.001 compared with the groups indicated by an arrow.
*p< 0.05, **p< 0.01, ***p< 0.001 compared with the controls, n= 12–15 per group and the data shown are mean ± standard mean error (SEM)
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Furthermore, previous studies reported that the peripheral
immune system plays a key role in deciding microglial
activation and phenotype and can lead to microglial
response [54, 59]. Taken together, it is speculated that
peripheral administration of IL-4/10 directly or indirectly
may affect microglial phenotypes across loosen BBB or
through the choroid plexus and blood–CSF barrier
(BCSF) or by modulating peripheral immune cells in CRS
mice.
Previous research has found a decrease in pro-
inflammatory cytokine release and an increase in IL-10
production from LPS stimulated-microglia with imipra-
mine treatment, which partially agrees with what we ob-
served in the hippocampus with CRS [60]. Although
several reports examined microglial activation using Iba-
1 as target of stress and antidepressants [10, 21–23],
normalization of morphological activation marker Iba-1
alone appears to be insufficient to represent and to ex-
plain microglial effector function. Recent studies have
demonstrated that microglial markers, such as CX3CR1,
CD200R, and CD206, have a close relationship in their
effector functions [19, 37]. Disturbance of these factors
may cause microglia to be non-functional; these factors
are suggested to be responsible for pathology of depres-
sion [10, 61]. CX3CR1 plays a crucial role in regulating
neurotoxicity of microglia, and its stimulation was found
to be anti-inflammatory [62, 63]. CX3CR1-deficienct
mice showed prolonged depression-like behavior in re-
sponse to LPS, which suggests that microglial activity
may cause a change in stress-related behaviors [62–64].
Especially, the hippocampus was known to have the
highest expression of ligand of CX3CR1 and was vulner-
able to the loss of CX3CR1 [10, 63]. In our study,
CX3CR1 was decreased in CRS, co-Imi+CRS, and (co-Imi
+CRS)+FS mice despite chronic imipramine co-treatment
in the hippocampus while it was normalized by IL-4/10.
Thus, our results suggest that M2 markers may be in-
volved in the mechanism of peripheral immunity affecting
CNS. This might be associated with restoring the impair-
ment in stress-coping response and ameliorating the vul-
nerability to an additional stressor in co-imi+CRS mice
after the imipramine discontinuation.
In this study, we examined increased ratio of IFN-γ to
IL-10 and decrease in serum TNF-α, IL-1β, and IL-6
levels in CRS mice, and these results appear to be in
contrast to most of the previous studies. Many studies
have reported increased level of circulating pro-
inflammatory cytokines in depression-like conditions
[6, 9, 39]. However, there are several studies that re-
ported a decrease or no change in pro-inflammatory
cytokines in depressive-like conditions, and they explained
this phenomena with hypothalamic–pituitary–adrenal
(HPA) axis hyperactivation, which inhibits the secretion of
pro-inflammatory cytokines [42, 45, 65–67]. In addition,
previous studies suggested that pro-inflammatory cyto-
kines might be a mere characteristic or a nonparticipating
factor of depression [46, 65]. In previous studies, dynamic
alterations were observed in inflammatory cytokines and
microglial function depending on parameters of the stress
model [10, 51]. Chronic unrelenting stress (prolonged re-
straint stress) was found to induce immunosuppression
and anti-inflammatory phenotype [68]. Therefore, what
we observed in this study may be one of many possible
immunological manifestations in major depression. Taken
together, it could be postulated that stress vulnerability
may be sufficiently induced by reduction in anti-
inflammatory cytokines and M2 microglia markers with-
out an increase in pro-inflammatory cytokines. However,
the further study will be required to elucidate this
hypothesis.
Conclusion
This study demonstrates that imipramine co-treatment
failed to prevent vulnerability to an additional stressor,
while it inhibited stress-related behaviors due to its anti-
stress effects. Rather than traditionally considered
depression-related factors, decrease in the peripheral and
hippocampal microglial M2 factors may be involved in the
stress-coping system and vulnerability to depressogenic
episodes after imipramine discontinuation. The stress vul-
nerability could be alleviated by supplement of IL-4 and
IL-10 in the co-imi+CRS group with reversal in expression
of M2 microglia markers. With a further study that at-
tempts to elucidate the underlying mechanism of IL-4 and
IL-10 and neuroimmune response by microglia, thera-
peutic intervention for stress-related disorders might be
optimized.
Additional file
Additional file 1: Supplementary materials. S1. Imipramine treatment
to naïve mice does not have any effect on depression-like behaviors. S2.
BALB/c Nude mice exhibit depressive-like behaviors and anxiety-like
behaviors upon brief exposure to acute foot shock stress while balb/c
mice with the same genetic background did not. S3. Effect of chronic
restraint stress and imipramine treatment on leukocyte counts in the
blood, spleen and lymph node. (DOC 255 kb)
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